Quick Facts
| Property | Value |
|---|---|
| Category | Relaxin Receptor Agonist Peptide |
| Risk Level | High/Experimental |
| Administration | Subcutaneous Injection |
| Typical Frequency | Daily |
| Estimated Half-Life | Limited Human Data Available |
| Primary Research Interest | Anti-Fibrotic Signaling / Tissue Remodeling |
This material is provided strictly for educational and informational purposes related to peptide research and experimental signaling compounds. B7-33 is a highly experimental peptide with limited human data and incompletely characterized safety profiles. Information presented here should not be interpreted as medical advice, treatment recommendations, or encouragement of unsupervised use.
1. Reconstitution Guide
- Vial Size: 10 mg
- Dilutant Type: BAC Water
- Amount of Dilutant Added: 3 mL
- Final Concentration: 3.33 mg/mL
At this concentration:
• 250 mcg = 0.075 mL (7.5 units)
• 500 mcg = 0.150 mL (15.0 units)
2. Route of Administration
B7-33 is most commonly discussed as a subcutaneous injectable peptide compound in experimental contexts.
- Primary Route: SubQ Injection
- Preferred Timing: Consistently timed daily administration
- Administration Notes: Due to limited human characterization, protocol consistency is often emphasized in experimental discussions
3. Typical Research Protocols
- Product Strength: 3.33 mg/mL
- Typical Delivered Amount: 250–500 mcg daily
- Frequency: Daily, consistently timed
- Cycle Length: 6–12 weeks on / 24 weeks off
- Special Notes: Long-term use is generally not recommended. Compared with mainstream peptides, B7-33 remains relatively obscure and poorly characterized in humans.
4. Summary
B7-33 is an experimental peptide derived from relaxin signaling research and designed to selectively activate specific relaxin-family receptor pathways.
Research interest in B7-33 has focused primarily on anti-fibrotic signaling, tissue remodeling, inflammation modulation, and potential cardiovascular applications.
5. Mechanism of Action
B7-33 is believed to function through selective activation of RXFP1 (relaxin family peptide receptor 1) signaling pathways.
Unlike broader relaxin signaling, B7-33 was designed to potentially isolate beneficial anti-fibrotic and tissue remodeling effects while minimizing some downstream hormonal signaling complexity.
Potential downstream mechanisms discussed in research include:
- Reduced fibrosis signaling
- Altered extracellular matrix remodeling
- Inflammation modulation
- Potential vascular effects
- Tissue repair pathway activation
6. Potential Benefits
- Potential anti-fibrotic activity
- Possible tissue remodeling support
- Inflammation modulation
- Potential cardiovascular support signaling
- Experimental tissue repair applications
7. Potential Risks / Side Effects
High/Experimental
- Limited human safety data
- Unknown long-term physiological effects
- Potential cardiovascular signaling alterations
- Hormonal pathway disruption concerns
- Injection site irritation
- Headaches
- Possible immune signaling alterations
8. Half-Life
Reliable human pharmacokinetic data for B7-33 remain extremely limited.
Most available information originates from experimental animal models and early-stage research discussions rather than large-scale clinical use.
9. Storage Information
- Store refrigerated before and after reconstitution
- Protect from direct light exposure
- Avoid repeated freeze-thaw cycles
- Maintain sterile handling practices during preparation
10. Contraindications / Warnings
- Pregnancy or breastfeeding
- Cardiovascular disease
- Active autoimmune disorders
- Known hypersensitivity to peptide compounds
- Use alongside experimental hormonal therapies
11. Research References
- PubMed
- NIH Publications
- Relaxin signaling research literature
- Peer-reviewed fibrosis and cardiovascular journals
CKF Tide Tables 